ReviewPituitary2020
Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review.
Review in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Patency of the Cavernous Sinus After Medial Wall Resection: An Observational Study.Journal of neurological surgery. Part B, Skull base · 2026Article
- Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.Clinical pharmacology in drug development · 2026Article
- Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study.Pituitary · 2026Article
- Outcome of acromegalic patients undergoing endoscopic endonasal surgery: collaborative French and Italian cohort, a 25-year experience.Neurosurgical review · 2025Article
- PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.Endocrine · 2025Article
- Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading.Neuroradiology · 2025Article
- Early Predictors of Remission in Acromegaly Patients after Pure Endoscopic Endonasal Transsphenoidal Surgery.Journal of neurological surgery. Part B, Skull base · 2025Article
- Predictors of growth hormone level on postoperative day one in patients with acromegaly.Endocrine · 2025Article
- Biochemical remission, diagnostic delays, and comorbidities of acromegaly in China: a large single-centre retrospective study.Frontiers in endocrinology · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly.Frontiers in endocrinology · 2025Article
- Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly.Journal of neuro-oncology · 2025Review
- Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients.Pituitary · 2024Article
- Does size really matter? A closer look at the absolute size of growth hormone-secreting pituitary adenomas.Pituitary · 2024Article
- The State of Machine Learning in Outcomes Prediction of Transsphenoidal Surgery: A Systematic Review.Journal of neurological surgery. Part B, Skull base · 2023Article
- Machine Learning Models to Forecast Outcomes of Pituitary Surgery: A Systematic Review in Quality of Reporting and Current Evidence.Brain sciences · 2023Review
- Efficiency and Safety of CyberKnife Robotic Radiosurgery in the Multimodal Management of Patients with Acromegaly.Cancers · 2023Article
- Gigantism: microsurgical treatment by transsphenoidal approach and prognostic factors.Pituitary · 2023Article
- Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBiochemical control is the main determinant of survival, clinical manifestations and comorbidities in acromegaly. Transsphenoidal selective adenomectomy (TSA) is the initial treatment of choice with reported biochemical remission rates varying between 32 and 85%. Understanding the limiting factors is essential for identification of patients who require medical treatment.
methodsWe reviewed the English literature published in Medline/Pubmed until Dec 31, 2019 to identify eligible studies that described outcomes of TSA as primary therapy and performed analyses to determine the main predictors of remission.
resultsMost publications reported single-institution, retrospective studies. The following preoperative parameters were consistently associated with lower remission rates: cavernous sinus invasion by imaging, larger tumor size and higher GH levels. Young age and preoperative IGF-1 levels were predictive in some studies. When controlled for covariates, the best single preoperative predictor was cavernous sinus invasion, followed by preoperative GH levels. Conversely, low GH level in the first few days postoperatively was a robust predictor of durable remission. The influence of tumor histology (sparsely granular pattern, co-expression of prolactin and proliferation markers) on surgical remission remains to be established. Few studies developed predictive models that yielded much higher predictive values than individual parameters.
conclusionSurgical outcome prognostication systems could be further generated by machine learning algorithms in order to support development and implementation of personalized care in patients with acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.